ATE520411T1 - Behandlung und prävention von lungenerkrankungen - Google Patents

Behandlung und prävention von lungenerkrankungen

Info

Publication number
ATE520411T1
ATE520411T1 AT03719918T AT03719918T ATE520411T1 AT E520411 T1 ATE520411 T1 AT E520411T1 AT 03719918 T AT03719918 T AT 03719918T AT 03719918 T AT03719918 T AT 03719918T AT E520411 T1 ATE520411 T1 AT E520411T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
methods
compositions
lung diseases
Prior art date
Application number
AT03719918T
Other languages
English (en)
Inventor
Charles G Cochrane
Zenaida G Oades
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE520411T1 publication Critical patent/ATE520411T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03719918T 2002-04-25 2003-04-25 Behandlung und prävention von lungenerkrankungen ATE520411T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37596802P 2002-04-25 2002-04-25
PCT/US2003/012731 WO2003090682A2 (en) 2002-04-25 2003-04-25 Treatment and prevention of pulmonary conditions

Publications (1)

Publication Number Publication Date
ATE520411T1 true ATE520411T1 (de) 2011-09-15

Family

ID=29270737

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03719918T ATE520411T1 (de) 2002-04-25 2003-04-25 Behandlung und prävention von lungenerkrankungen

Country Status (13)

Country Link
US (2) US7863241B2 (de)
EP (1) EP1558273B1 (de)
JP (2) JP4651946B2 (de)
KR (2) KR101036058B1 (de)
CN (1) CN1838964A (de)
AT (1) ATE520411T1 (de)
AU (1) AU2003223718B2 (de)
CA (1) CA2483102C (de)
IL (2) IL164795A0 (de)
MX (1) MXPA04010560A (de)
NZ (1) NZ536796A (de)
WO (1) WO2003090682A2 (de)
ZA (1) ZA200408573B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1838964A (zh) 2002-04-25 2006-09-27 斯克里普斯研究学院 肺病的治疗与预防
CA2549160A1 (en) * 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma
WO2005073246A2 (en) * 2004-01-20 2005-08-11 Discovery Laboratories, Inc. Method for preparing kl4 lung surfactant
JP4160615B2 (ja) * 2004-03-11 2008-10-01 レドックス・バイオサイエンス株式会社 プロテアーゼ阻害剤
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US7468350B2 (en) 2004-06-16 2008-12-23 Pneumrx, Inc. Glue composition for lung volume reduction
WO2006014567A2 (en) 2004-07-08 2006-02-09 Pneumrx, Inc. Pleural effusion treatment device, method and material
JP2008512403A (ja) * 2004-09-10 2008-04-24 ファルマオリジン・アンパルトセルスカブ 局所的な気管、気管支、または肺胞の出血または喀血の治療方法
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
CN101094651B (zh) * 2004-12-30 2011-03-09 多贝尔有限公司 含有胶原凝集素家族蛋白质或者其变体的喷雾干燥的组合物和其制备方法
GB0510463D0 (en) * 2005-05-23 2005-06-29 Britania Pharmaceuticals Ltd Improvements in or relating to organic materials
US8088728B2 (en) * 2005-06-24 2012-01-03 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
WO2007005672A2 (en) * 2005-06-30 2007-01-11 The Scripps Research Institute Treatment and prevention of respiratory diseases and conditions
AU2008232677B2 (en) * 2007-03-29 2013-09-19 National Jewish Health Surfactant lipids, compositions thereof, and uses thereof
EP1997502A1 (de) * 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Rekonstituierte Tenside mit verbesserten Eigenschaften
CA2690089A1 (en) * 2007-06-05 2008-12-11 Paka Pulmonary Pharmaceuticals, Inc. Lung surfactant drug conjugates and uses thereof
US20110142914A1 (en) * 2007-12-06 2011-06-16 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
GB0724772D0 (en) * 2007-12-19 2008-01-30 Ucl Business Plc Carrier
WO2010068754A2 (en) * 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
EP2391379B1 (de) 2009-01-30 2017-08-02 Alphabeta AB Verbindungen und verfahren zur behandlung von morbus alzheimer
US8434479B2 (en) 2009-02-27 2013-05-07 Covidien Lp Flow rate compensation for transient thermal response of hot-wire anemometers
JP5622728B2 (ja) * 2009-08-06 2014-11-12 一般財団法人化学及血清療法研究所 咳嗽抑制効果を持つ血漿タンパク質
EP2711004A1 (de) * 2009-10-05 2014-03-26 Nutri-Fit GmbH & Co. KG Verfahren zur Erhöhung der physikalischen Kapazität einer Säugetierunterkunft
EP2496246B1 (de) * 2009-11-03 2018-06-27 Grifols Therapeutics LLC Zusammensetzung, verfahren und kit für einen alpha-1-proteasehmmer
JP5810091B2 (ja) 2009-11-24 2015-11-11 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 凍結乾燥方法、組成物、及びキット
GB201003559D0 (en) * 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
PE20130045A1 (es) 2010-03-12 2013-01-28 Berg Pharma Llc FORMULACIONES INTRAVENOSAS DE COENZIMA Q10 (CoQ10) Y METODOS DE USO DE LAS MISMAS
US8785391B2 (en) 2010-06-24 2014-07-22 Alphabeta Ab Compound and method for treatment of alzheimer's disease and familial dementia
CN101897720B (zh) * 2010-07-27 2015-09-09 北京华禧联合科技发展有限公司 一种治疗呼吸道疾病的药物组合物
AU2011323205A1 (en) * 2010-11-04 2013-06-27 The Board Of Regents Of The University Of Oklahoma Peptide compositions that downregulateTLR-4 signaling pathway and methods of producing and using same
US20130184202A1 (en) * 2011-02-08 2013-07-18 Changjiang Guo Peptide Inhibitors and Methods of Use Thereof
WO2012138284A1 (en) 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
EP2696888B1 (de) * 2011-04-12 2018-12-05 Moerae Matrix, Inc., Zusammensetzungen und verfahren zur prävention oder behandlung von lungenfibrose
KR102058256B1 (ko) 2011-06-17 2020-01-22 버그 엘엘씨 흡입성 약제학적 조성물들
US9089657B2 (en) 2011-10-31 2015-07-28 Covidien Lp Methods and systems for gating user initiated increases in oxygen concentration during ventilation
WO2013188016A2 (en) * 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation
JP2016536343A (ja) * 2013-09-18 2016-11-24 ジェームス・クック・ユニバーシティー 抗炎症性のタンパク質及び使用方法
JP2016532456A (ja) 2013-09-18 2016-10-20 ジェームス・クック・ユニバーシティー 改変型抗炎症性タンパク質及び使用方法
WO2015061412A1 (en) * 2013-10-22 2015-04-30 The Scripps Research Institute Methods and compositions for promoting bronchioli dilatation
US20180221462A1 (en) * 2014-08-26 2018-08-09 Proteo Biotech Ag Use of elafin for disorders associated with elastase independent increase in troponin
EP3300474A4 (de) 2015-04-27 2019-01-30 OmniActive Health Technologies Limited Bettubustoxinzusammensetzungen, verfahren zu ihrer herstellung und verwendungen davon
US10239847B1 (en) 2016-03-03 2019-03-26 Cellactin Method for 2-oxothiazolidine-4-carboxylic acid for cellular glutathione
US20190269765A1 (en) * 2016-09-13 2019-09-05 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
AU2018241248A1 (en) * 2017-03-31 2019-09-05 Ena Respiratory Pty Ltd Treatment of respiratory infection with a TLR2 agonist
AU2018392461A1 (en) * 2017-12-21 2020-07-02 Civitas Therapeutics, Inc. Surfactant formulations for inhalation
US20210145741A1 (en) * 2018-04-17 2021-05-20 Lamellar Biomedical Limited Antifibrotic composition
AU2019321654A1 (en) * 2018-08-17 2021-03-18 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of acute lung injury
US20210332106A1 (en) * 2018-10-19 2021-10-28 Ohio State Innovation Foundation Nanocarriers for lung inflammation therapy
US20220000966A1 (en) * 2018-10-23 2022-01-06 George Edward Hoag Composition and method for treating the lungs
CA3116015A1 (en) * 2018-10-30 2020-05-07 University Of Florida Research Foundation, Incorporated Amino acid compositions and methods for treating cystic fibrosis
CA3145702A1 (en) * 2019-08-01 2021-02-04 Philip A. Pemberton Oxidation-resistant serpins
KR102276935B1 (ko) * 2020-02-06 2021-07-12 한양대학교 산학협력단 신규한 비올라크산틴 고생산 클로렐라 불가리스 균주 및 이로부터 비올라크산틴을 생산하는 방법
KR20220166835A (ko) * 2020-04-08 2022-12-19 아리조나 보드 오브 리전츠 온 비해프 오브 더 유니버시티 오브 아리조나 폐 질환을 치료하고 예방하기 위한 조성물과 방법
CN115245559A (zh) * 2021-04-25 2022-10-28 上海萨美细胞技术有限公司 一种用于治疗肺损伤的药物
WO2024097169A1 (en) * 2022-11-01 2024-05-10 National Jewish Health Treatment of coronavirus infections with antimicrobial phospholipid compositions
CN116421704A (zh) * 2023-02-20 2023-07-14 成都佩德生物医药有限公司 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57144224A (en) * 1981-03-02 1982-09-06 Mochida Pharmaceut Co Ltd Remedy for respiratory dieseases
US4916117A (en) * 1986-12-24 1990-04-10 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US5164369A (en) * 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US5260273A (en) 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff
ATE201880T1 (de) * 1989-07-11 2001-06-15 Genentech Inc Oberflächenaktive zusammensetzungen und verfahren
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5272252A (en) * 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
DE69313647T2 (de) * 1992-07-31 1998-03-12 Merrell Pharmaceuticals Inc., Cincinnati, Ohio Synthetische peptide als lungensurfactants mit kovalent gebundenen antioxidantien
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5301644A (en) 1993-06-16 1994-04-12 Kohler Co. Fuel shut-off mechanism for internal combustion engines
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US6008196A (en) * 1994-06-02 1999-12-28 Hoechst Marion Roussel, Inc. Perfluoroalkyl ketone inhibitors of elastase and processes for making the same
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5878912A (en) 1995-12-26 1999-03-09 Stein; Myron Duct disinfecting method and apparatus
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
WO1998029141A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
US6051257A (en) 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
JPH11147832A (ja) * 1997-11-18 1999-06-02 Noevir Co Ltd 好中球エラスターゼ阻害剤
JP3796340B2 (ja) * 1997-11-18 2006-07-12 株式会社ノエビア セリンプロテアーゼ阻害剤
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US5883084A (en) * 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
US6223455B1 (en) 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
EP1216052A1 (de) 1999-09-16 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Kombination eines c1-inh und eines lungensurfactant zur behandlung von respirationstörungen
IL150485A0 (en) * 1999-12-28 2002-12-01 Novartis Ag Method of achieving persistent transgene expression
AU2908501A (en) * 2000-01-06 2001-07-16 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
CN1838964A (zh) 2002-04-25 2006-09-27 斯克里普斯研究学院 肺病的治疗与预防
US6819898B2 (en) * 2002-11-22 2004-11-16 Kabushiki Kaisha Toshiba Image forming apparatus including stopping member and backstop member to stop rotation of revolver type developing unit

Also Published As

Publication number Publication date
ZA200408573B (en) 2006-03-29
AU2003223718B2 (en) 2007-08-16
US20050070477A1 (en) 2005-03-31
IL164795A (en) 2011-02-28
EP1558273B1 (de) 2011-08-17
NZ536796A (en) 2007-03-30
CA2483102A1 (en) 2003-11-06
KR20110017465A (ko) 2011-02-21
JP2011001383A (ja) 2011-01-06
KR20050019073A (ko) 2005-02-28
WO2003090682A3 (en) 2004-09-16
AU2003223718C1 (en) 2003-11-10
US20120189602A1 (en) 2012-07-26
WO2003090682A2 (en) 2003-11-06
EP1558273A4 (de) 2008-07-16
US7863241B2 (en) 2011-01-04
MXPA04010560A (es) 2005-08-15
KR101036058B1 (ko) 2011-05-19
JP2005529885A (ja) 2005-10-06
CA2483102C (en) 2013-06-18
IL164795A0 (en) 2005-12-18
JP4651946B2 (ja) 2011-03-16
EP1558273A2 (de) 2005-08-03
CN1838964A (zh) 2006-09-27
AU2003223718A1 (en) 2003-11-10

Similar Documents

Publication Publication Date Title
ATE520411T1 (de) Behandlung und prävention von lungenerkrankungen
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE451369T1 (de) Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
CY1116992T1 (el) Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17
NO20034056D0 (no) Proliferative sykdommer
MEP90508A (en) New pharmaceutical composition
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
DE60131160D1 (de) Caspase-inhibitoren und ihre verwendungen
DE60310991D1 (de) Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
DOP2002000525A (es) Inhibidores del factor xa y de otras proteasas de serina implicadas en la cascada de la coagulacion.
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DK1163208T3 (da) Caspaseinhibitorer og anvendelser deraf
TR200002940T2 (tr) Parazitlerin sebep olduğu hastalıkların papain süperfamilyasından sistein proteazların inhibisyonu yoluyla tedavisi
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
DK0871454T3 (da) Phosphorholdige inhibitorer af cystein- og serinprotease
DE60026279D1 (de) Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
HK1029936A1 (en) Quinoline-containing alpha-ketoamide cysteine and serine protease inhibitors
CY1105166T1 (el) Ενωσεις φωσφονικου οξεος σαν αναστολεις πρωτεασων σepινης
DE60220385D1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE60329326D1 (de) Tace inhibitoren
ATE428425T1 (de) Spla2-inhibitoren zur behandlung von arteriosklerose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties